Washington: Scientists have used a new approach to identify compounds with the potential to delay or treat Alzheimer`s disease, and possibly Parkinson`s, Lou Gehrig`s disease and other degenerative disorders. All of these diseases are marked by harmful, elongated, rope-like structures known as amyloid fibrils, linked protein molecules that form in the brains of patients. The new structure-based approach to drug design, in which the physical structure of a targeted protein is used to help identify compounds that will interact with it, has already been used to generate therapeutic agents for a number of infectious and metabolic diseases.
New device uses handwriting to detect neurological disorders
Genetic mutation linked to congenital heart disease identified